Castrate Resistant Prostate Cancer Market is Anticipated to Witness High Growth Due to Increasing Prevalence of Prostate Cancer

Castrate Resistant Prostate Cancer Market


 Castrate resistant prostate cancer is an advanced stage of prostate cancer that does not respond to androgen deprivation therapy. Increasing prevalence of prostate cancer and rising demand for advanced treatment options are major factors contributing to growth of the castrate resistant prostate cancer market.

The Global Castrate Resistant Prostate Cancer Market Demand is estimated to be valued at US$ 12.82 billion in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period from 2024 to 2030.

Prostate cancer is one of the most commonly occurring cancers in men. According to the National Cancer Institute, there were around 268,490 new cases of prostate cancer in the United States in 2022. Androgen deprivation therapy is the standard treatment for advanced prostate cancer. However, in many cases the cancer becomes resistant to androgen deprivation over time and continues to progress, leading to castrate resistant prostate cancer (CRPC). Drugs for treating CRPC play a crucial role in improving survival and quality of life of patients. Some of the key advantages of CRPC drugs include improved therapeutic efficacy and reduced risks of cancer recurrence and death. With rising incidence of prostate cancer cases and limited treatment alternatives for late-stage CRPC, the demand for effective CRPC drugs is increasing significantly.

Key Takeaways
Key players operating in the castrate resistant prostate cancer market include Bayer AG, Johnson & Johnson, Amgen, Pfizer, AstraZeneca, Sanofi, and Astellas Pharma. Bayer’s Nubeqa and J&J’s Erleada are among the top-selling CRPC drugs.

North America dominates the global CRPC drugs market due to growing patient pool, favourable reimbursement policies, and high adoption of novel therapeutics. According to Prostate Cancer Foundation, around 268,000 new prostate cancer cases will be diagnosed in United States in 2022.

Key players are investing heavily in R&D to develop innovative treatment approaches for advanced prostate cancer. partnerships and acquisition activities are also on a rise to enhance product pipelines. In 2023, Darna BioSciences raised $80 million to advance pipeline of novel CRPC therapeutics.

Rising geriatric population worldwide presents significant growth opportunities. Asia Pacific region is anticipated to witness fastest growth during the forecast period supported by improving access toancer healthcare in China and India.

Market Drivers
Prevalence of prostate cancer is increasing rapidly worldwide driven by aging population and changing lifestyle factors. According to WHO, incidence rates of prostate cancer are highest in developed countries. Growing patient pool is the primary driver of CRPC therapeutics market.

Market Restraints
High cost of CRPC drugs limits their adoption in developing nations. For instance, average cost of CRPC treatment exceeds $120,000 per patient in the US. Existing therapies also have severe side effects such as fatigue, diarrhoea, & bone pain, reducing patient compliance. Stringent regulatory approval process also restrains market growth.


Segment Analysis

There are 3 main segments of the castrate resistant prostate cancer market - chemotherapy, hormonal therapy, and targeted therapy. The targeted therapy segment currently dominates the market owing to the better efficacy and lesser side effects offered by targeted drugs such as abiraterone, enzalutamide, and sotirilimab used in targeted therapy. Within targeted therapy, the immunotherapies sub-segment shows the most promise for future growth since immune checkpoint inhibitors have shown survival benefits and are being increasingly used in treatment protocols.

Global Analysis

North America has the largest share in the castrate resistant prostate cancer market currently due to high awareness levels, advanced healthcare infrastructure, favorable reimbursement policies, and presence of major market players in the region. It is expected to continue dominating the market during the forecast period. However, the Asia Pacific region is likely to grow at the fastest CAGR during this period owing to rising healthcare expenditure, growing geriatric population, increasing adoption of advanced treatment options, and healthcare reforms across many countries in the region.

Get more insights on this topic: Castrate Resistant Prostate Cancer Market

Comments

Post a Comment

Popular posts from this blog

The Global Electric Powertrain Market Poised for Growth Driven by Sustainable Transportation

Image
  Electric Powertrain Market The global electric powertrain market is seeing rapid adoption as consumers seek more environmentally friendly transportation options. Electric powertrains offer much lower operating costs than internal combustion engines while also being more energy efficient with fewer moving parts. Battery electric vehicles and hybrids containing electric motors and batteries are able to deliver torque instantly for smooth acceleration and regenerative braking that captures kinetic energy to charge the batteries while slowing down. Automakers are developing advanced powertrain technologies that combine smaller, lighter electric motors with improved batteries capable of longer ranges between charges. The global Electric Powertrain Market is estimated to be valued at US$ 94.12 Mn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market key trends: One of the majo
Read more

The Bladder Liners Market Is Estimated To Witness High Growth Owing To Rising Prevalence Of Urinary Incontinence

Image
  Bladder Liners Market Market Overview: Benzodiazepines are a class of psychoactive drugs belonging to the benzodiazepine family. These drugs are prescribed for various medical conditions such as anxiety disorders, panic disorders, insomnia, seizures, alcohol withdrawal syndrome, muscle spasms, and as an anesthesia aid. Some common examples of benzodiazepines include alprazolam, clonazepam, diazepam, and lorazepam. These drugs work by increasing the action of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system. Due to their calming properties, they are widely used to treat insomnia, anxiety, panic attacks, agitation, seizures, muscle spasms, and alcohol withdrawal. Market Dynamics: The Benzodiazepine Drugs Market is primarily driven by the rising prevalence of anxiety disorders worldwide. As per Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S., affecting nearly 40 million adul
Read more

Poultry Market is Expected to be Flourished by Growing Demand for Protein-Rich Food

Image
Poultry Market The poultry market comprises farming of domesticated birds such as chickens, ducks, turkeys, and geese, primarily for their meat and eggs. Poultry meat is one of the most consumed meats globally owing to its high protein content. Chicken is the most commonly produced meat worldwide, with over 95 million tons produced annually. Poultry farming provides affordable animal protein to consumers while generating income and employment for farmers and allied industries. The global poultry industry includes large integrated production facilities, small commercial farms, and backyard flock operations. Technological advancements have increased efficiency in breeding, hatching, feeding, housing, and disease control. The global poultry market is estimated to be valued at US$ 15.88 billion in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: One of the key driv
Read more